Tumor metastasis inhibiting compounds and methods

Details Tumor metastasis inhibiting compounds and methods Tumor metastasis inhibiting compounds and methods

1992-02-13

1995-07-25

Warden, Jill

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 13, 514 14, 514 15, 514 16, 514 17, 514 18, 530324, 530325, 530326, 530327, 530328, 530337, 530330, 530331, A61K 3800, C07K 500, C07K 700, C07K 1400

Patent

active

054362210

ABSTRACT:
A peptide derivative containing 1 to 20 units of peptide unit represented by the following general formula [I] or a pharmaceutically acceptable salt thereof;

REFERENCES:
patent: 4505853 (1985-03-01), Goldstein et al.
Mazerolles et al, Cell, vol. 55, No. 3, 1988, pp. 497-504.
Piatier-Tonneau et al., PNAS, vol. 88, 8/91, pp. 6858-6862.
Cell, vol. 55, No. 3, Nov. 4, 1988, pp. 497-504, Cambridge, Mass., US; F. Mazerolles et al. "Immunosuppressive properties of synthetic peptides derived from CD4 and HLA-DR antigens".
Proceedings of the National Academy of Sciences, USA, vol. 81, No. 19, Oct. 1984, pp. 5985-5988; M. D. Pierschbacher et al.: "Variants of the cell recognition site of fibronectin that retain attachment-promoting activity".
The Journal of Biological Chemistry, Vo. 264, No. 22, Aug. 5, 1989, pp. 13102-13108, The American Society for Biochemistry and Molecular Biology, Inc., US: B. Steiner et al.: "Ca.sup.2+ --dependent binding of a synthetic Arg-Gly-Asp (RDG) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex".
Hoppe-Seyler's Z. Physiol. Chem., vol. 364, Aug. 1983, pp. 933-940; L. Kisfaludy et al.: "Immuno-regulating peptides, I. Synthesis and structure-activity relationships of thymopentin analogs".
Chemical Abstracts, vol. 114, No. 9, Mar. 4, 1991, p. 481, Abstract No. 79202w, Columbus, Ohio, US.
J. B. Lawrence et al.: "Arginine-glycine-aspartic acid-and fibrinogen gamma-chain carboxyterminal peptides inhibit platelet adherence to arterial subendothelium at high wall shear rates: an effect dissociable from interference with adhesive protein binding", J. Clin. Invest. 1190, 86(5), 1715-22.
Chemical Abstracts, Vo. 113, No. 5, Jul. 30, 1990, p. 425, Abstract No. 38496f, Columbus, Ohio, US.
F. Mazerolles et al.: "Regulation of T helper-B lymphocyte adhesion trough CD4-HLA class II interaction", & Eur. J. Immunol. 1990, 20(3), 637-44.
Chemical Abstracts, vol. 109, No. 1, Jul. 4, 1988, p. 355, Abstract No. 3715s, Columbus, Ohio, US.
M. A. Quaissi et al.: "Fluorescence-activated cell-sorting analysis of fibronectin peptides binding to Trypasnosoma cruzi trypomastigotes", & J. Protozool. 1099, 35(1), 111-14.
Chemical Abstracts, vol. 105, No. 3, Jul. 21, 1986, p. 516, Abstract No. 22866a, Columbus, Ohio, US.
C. Auffray et al.: "Speculation on sequence homologies between the fibronectin cell-attachment site, major histocompatibility antigens, and a putative AIDS virus polypeptide", & Hum. Immunol. 1986, 15(4) 381-90.

Affiliated with

Also associated with

Rating

Tumor metastasis inhibiting compounds and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor metastasis inhibiting compounds and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor metastasis inhibiting compounds and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-739646